Carcinoembryonic antigen expression in stages I and II breast cancer: Its relationship with clinicopathologic factors
Carcinoembryonic antigen expression in stages I and II breast cancer: Its relationship with clinicopathologic factors
复制标题
DOI：
10.1016/s0046-8177(96)90072-6
复制
发表时间：
1996-03-01
期刊：
影响因子：
3.3
通讯作者：
Ricci, L
中科院分区：
文献类型：
--
作者：
Sundblad, AS;Pellicer, EM;Ricci, L
癌胚抗原（CEA）在乳腺癌中的表达已被免疫组化检测到，但其与预后的关系尚不清楚。这种困难可能是因为用于其测定的抗体种类繁多。在本研究中，271 I期和II期乳腺癌进行了免疫组化分析，使用T84.66抗体，一个众所周知的高度特异性CEA抗体。结果表明，CEA表达与分析的任何临床病理因素无关。单因素Logistic回归分析显示，肿瘤大小小于2cm是影响无病生存率的因素（P = .01），淋巴结无转移（P = 0.0000），低核等级（P = 0.007），无c-erbB-2过表达（P = 0.02）和bcl-2（P = 0.005）和CEA表达（P = .005），而与更好的总生存期（OS）显著相关的是肿瘤大小小于2 cm（P = 0.002）、淋巴结无转移（P = 0.0001）、低核分级（P = 0.01）、低组织学分级（P = 0.02）、无c-erbB-2过表达（P = 0.002）和bcl-2表达（P = 0.01）。经多因素逐步回归分析，淋巴结无转移（P = .0000），CEA表达（P = 0.001），无c-erbB-2过表达（P = .01），bcl-2表达（P = .01）是DFS的独立相关因素，而无淋巴结转移（P = 0.0000）、肿瘤大小小于2 cm（P = 0.0000）和无c-erbB-2过表达（P = 0.004）与较好的OS相关。这些结果表明，用抗体T84.66进行CEA免疫组化检测可能是建立乳腺癌预后的一个额外因素。(C)1996年，W.B.桑德斯公司
Carcinoembryonic antigen (CEA) has been detected by immunohistochemistry in breast carcinoma, but its relationship with prognosis is still unclear. This difficulty may be because of the great variety of antibodies used for its determination. In the present study, 271 stages I and II breast carcinomas are analyzed by immunohistochemistry, using the T84.66 antibody, a well-known highly specific CEA antibody. The results show that CEA expression was not associated with any of the clinicopathologic factors analyzed. Factors associated with disease-free survival (DFS) after univariate logistic regression analyses were tumor size smaller than 2 cm (P = .01), lymph node free of metastases (P = .0000), low nuclear grade (P = .007), absence of c-erbB-2 overexpression (P = .02), and bcl-2 (P = .005) and CEA expression (P = .005), whereas those significantly associated with a better overall survival (OS) were tumor size smaller than 2 cm (P = .002), lymph node free of metastases (P = .0001), low nuclear grade (P = .01), low histological grade (P = .02), absence of c-erbB-2 overexpression (P = .002) and bcl-2 expression (P = .01). After multivariate stepwise regression analysis, lymph node free of metastases (P = .0000), CEA expression (P = .001), absence of c-erbB-2 overexpression (P = .01), and bcl-2 expression (P = .01) were found to be independent factors associated with DFS, whereas lymph node free of metastases (P = .0000), tumor size smaller than 2 cm (P = .0000), and absence of c-erbB-2 overexpression (P = .004) were associated with a better OS. These results show that immunohistochemical detection of CEA with the antibody T84.66 may be useful as an additional factor in establishing breast cancer prognosis. (C) 1996 by W.B. Saunders Company